Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMALRCH)

Drug Name
Phaclofen Drug Info
Synonyms
Phaclofen; 114012-12-3; [3-amino-2-(4-chlorophenyl)propyl]phosphonic acid; (3-Amino-2-(4-chlorophenyl)propyl)phosphonic acid; Phosphonic acid, (3-amino-2-(4-chlorophenyl)propyl)-; 3-Amino-2-(4-chlorophenyl)propylphosphonic acid; 3-Amino-2-(4-chlorophenyl) propylphosphonic acid; Phosphonic acid,P-[3-amino-2-(4-chlorophenyl)propyl]-; SR-01000075640; Phaclofen, solid; beta-(4-Chlorophenyl)-3-aminopropylphosphonic acid; ACMC-20djlx; 108351-35-5; AC1Q3NDJ; AC1L1BWO; Biomol-NT_000256; Lopac0_000967; SCHEMBL339995; GTPL1091
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
1641
CAS Number
CAS 114012-12-3
TTD Drug ID
DMALRCH

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Gamma-aminobutyric acid B receptor (GABBR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gabapentin DM6T924 Complex partial seizure 8A68.0 Approved [3]
Gamma Hydroxybutyric Acid DMGBKVD Narcolepsy 7A20 Approved [4]
Baclofen DM0QV1J Multiple sclerosis 8A40 Approved [5]
Progabide DM671NG Depression 6A70-6A7Z Approved [6]
Arbaclofen placarbil DMO628K Fragile X syndrome LD55 Phase 3 [7]
[3H](R)-(-)-baclofen DMLRHM5 Multiple sclerosis 8A40 Phase 3 [8]
Arabaclofen DMZB9RI Fragile X syndrome LD55 Phase 3 [9]
GSK683699 DMTW79H Inflammatory bowel disease DD72 Phase 2 [10]
SGS742 DM5XYFH Schizophrenia 6A20 Phase 2 [11]
SSTarbaclofen DMRGTZ2 Autism spectrum disorder 6A02 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gamma-aminobutyric acid B receptor (GABBR) TTDCVZW GABR1_HUMAN; GABR2_HUMAN Antagonist [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1091).
2 Astrocytes and interneurons in memory processing in the chick hippocampus: roles for G-coupled protein receptors, GABA(B) and mGluR1. Neurochem Res. 2009 Oct;34(10):1712-20.
3 Gabapentin increases a tonic inhibitory conductance in hippocampal pyramidal neurons. Anesthesiology. 2006 Aug;105(2):325-33.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 Synthesis and pharmacology of the baclofen homologues 5-amino-4-(4-chlorophenyl)pentanoic acid and the R- and S-enantiomers of 5-amino-3-(4-chlorop... J Med Chem. 1999 Jun 3;42(11):2053-9.
6 Interactions between dopamine and GABA in the control of ambulatory activity and neophobia in the mouse. Pharmacol Biochem Behav. 1998 Jan;59(1):239-47.
7 Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen.J Pharmacol Exp Ther.2009 Sep;330(3):911-21.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 242).
9 Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl). 2013 Jul;228(1):75-84.
10 3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. J Med Chem. 1991 Aug;34(8):2557-60.
11 SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol. 2004 Oct 15;68(8):1479-87.
12 Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med. 2012 Sep 19;4(152):152ra128.